The Potential of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for Colorectal Cancer Prevention

Journal of Surgical Oncology

Volumn 84, Issue 3, 2003, Pages 113-119

  Bertagnolli, Monica M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; FOLIC ACID; ICOSANOID; LIPOXYGENASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPID; PIROXICAM; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; PROSTANOID; ROFECOXIB; SELENIUM; THROMBOXANE A2; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ARACHIDONIC ACID METABOLISM; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; COLON ADENOMA; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; DNA REPAIR; DRUG MECHANISM; EDITORIAL; ENZYME INHIBITION; HUMAN; INFLAMMATION; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RECTUM ADENOMA; THROMBOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONIC ACIDS; ASPIRIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; EICOSANOIDS; HUMANS; MEMBRANE LIPIDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RABBITS; RECEPTORS, PROSTAGLANDIN;

EID: 0242298575     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10279     Document Type: Editorial

References (53)

1. Fasching U, Eberl R: Sulindac: Clinical test of a new antiinflammatory agent in rheumatoid arthritis. Wein Klin Wochenschr Suppl 1976;59:1-10.
2. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-87.
3. Waddell WR, Ganser GF, Cerise EJ, et al.: Sulindac for polyposis of the colon. Am J Surg 1989;157:175-179.
4. Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
5. Giardiello FM, Yang VW, Hylind LM, et al.: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059.
6. Labayle D, Fischer D, Vielh P, et al.: Sulindac causess regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.
7. Nugent KP, Farmer KC, Spigelman AD, et al.: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-1619.
8. Steinbach G, Lynch PM, Phillips RKS, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
9. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:4.
10. Baron JA, Cole BF, Mott LA: Aspirin chemoprevention of colorectal adenomas. Proc Am Assoc Can Res 2002;43:669.
11. Piper PJ, Vane JR: Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 1969;223:29-35.
12. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
13. Marks F, Muller-Decker K, Furstenberger G: A causal relationship between unscheduled eicosanoid signaling and tumor development: Cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology 2000;153:11-26.
14. 2 production by suppressor monocytes in head and neck cancer patients. Ann Surg 1982;196:645-650.
15. Bennett A, Tacca MD, Stamford IF, et al.: Prostaglandins from tumour of human large bowel. Br J Cancer 1977;6:881-884.
16. Seyberth HW, Segre GV, Morgan JL, et al.: Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 1975;293:1278-1283.
17. Smith BJ, Wills MR, Savory J: Prostaglandins and cancer. Ann Clin Lab Sci 1983;13:359-365.
18. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-5589.
19. Maser RS, DePinho RA, Connecting chromosomes, crisis, and cancer. Science 2002;297:565-569.
20. Lim H, Dey SK: A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002;143:3207-3210.
21. He TC, Chan TA, Vogelstein B, et al.: PPARdelta is an APC-regulated target of nonsteroidal antiinflammatory drugs. Cell 1999;99:335-345.
22. Funk CD: Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001;294:1871-1875.
23. O'Banion MK, Sadowski HB, Winn V, et al.: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-23267.
24. Bazan NG, Flower RJ: Lipid signals in pain control. Nature 2002;420:135-138.
25. Chandrasekharan NV, Dai H, Roos KL, et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13371-13373.
26. Jakobsson PJ, Thoren S, Morgenstern R, et al.: Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220-7225.
27. Coleman RA, Smith WL, Narumya S: IUP classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharm Rev 1994;46:205-229.
28. Fosslein E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
29. Marnett LJ, Kalgutkar AS: Cyclooxygenase 2 inhibitors: Discovery, selectivity, and the future. TIPS 1999;20:465-469.
30. Liu CH, Chang SH, Narko K, et al.: Overexpression of cyclooxygenase-2 insufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
31. Jacoby RF, Seibert K, Cole CE, et al.: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044.
32. Oshima M, Dinchuk JE, Kargman SL, et al.: Suppression of intestinal polyposis in Apc delta knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
33. 2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-6711.
34. Masferrer JL, Leahy KM, Koki AT, et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
35. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90:1609-1620.
36. Sonoshita M, Takaku K, Oshima M, et al.: Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002;62:6846-6849.
37. Sonoshita M, Takaku K, Sasaki N, et al.: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta 716) knockout mice. Nat Med 2001;7:1048-1051.
38. Koki AT, Leahy JM, Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp Opin Invest Drugs 1999;8:1623-1638.
39. 2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214-218.
40. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
41. Leahy JM, Ornberg RL, Wang Y, et al.: Cyclooxygenase-2 inhibition by celecoxib reduces proliferafion and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-631.
42. Hixon LJ, Alaberts DX, Krutzsch M, et al.: Antiproliferative effect of nonsteroidal anti-inflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994;3:433-438.
43. Piazza GA, Rahm AL, Krutzsch M, et al.: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-3116.
44. Piazza GA: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997;57:2452-2459.
45. Piazza GA, Alberts DS, Hixon LJ, et al.: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-2915.
46. Piazza GA, Thompson WJ, Pamukcu R, et al.: Exisulind, a novel proapoptic drug, inhibits rat urinary bladder tumorgenesis. Cancer Res 2001;61:3961-3968.
47. Brash AR: Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999;274:23679-23682.
48. Shureiqi I, Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-6312.
49. Shureiqi I, Chen D, Lee JJ, et al.: 15-LOX-1: A novel molecular target of non steroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000;92:1136-1142.
50. Shureiqi I, Chen D, Lotan R, et al.: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-6850.
51. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al.: Treatment and prevention of intraepithelial neoplasia: An important target for accelerted new agent development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia. Clin Cancer Res 2002;8:314-346.
52. Leval X, Julemont F, Delarge J, et al.: New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002;9:941-962.
53. Ma J, Stampfer MJ, Christensen B, et al.: A polymorphism of the methionine synthase gene: Association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:825-829.